 |
Video: What is a Stock Split?
|
 |
| Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company. Co. is focused on discovering and developing medicines in the field of immunotherapy. Co. has a research and development pipeline of investigational medicines in immunology and oncology. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body's immune response to fight cancer. Its pipeline includes NKTR-255, Rezpegaldesleukin (REZPEG) and NKTR-0165. NKTR-255 is an investigational biologic that is designed to target the interleukin-15 (IL-15) pathway in order to activate the body's innate and adaptive immunity. According to our NKTR split history records, Nektar Therapeutics has had 1 split. | |
 |

Nektar Therapeutics (NKTR) has 1 split in our NKTR split history database. The split for NKTR took place on June 09, 2025. This was a 1 for 15 reverse split, meaning for each 15 shares of NKTR owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 66.6666666666667 share position following the split.
When a company such as Nektar Therapeutics conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the NKTR split history from start to finish, an original position size of 1000 shares would have turned into 66.6666666666667 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Nektar Therapeutics shares, starting with a $10,000 purchase of NKTR, presented on a split-history-adjusted basis factoring in the complete NKTR split history.

Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
03/11/2016 |
|
| End date: |
03/10/2026 |
|
| Start price/share: |
$193.05 |
|
| End price/share: |
$72.07 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-62.67% |
|
| Average Annual Total Return: |
-9.38% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$3,734.57 |
|
| Years: |
10.00 |
|
|
 |
| Date |
Ratio |
| 06/09/2025 | 1 for 15 |
|
 |